phentolamine mesylate
AssetAlso Nyxol, NV-101, Oraverse, Regitine
Blocks alpha-adrenergic receptors in the iris, reducing pupil diameter to improve night vision.
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- ADRA2A
- 3
- Indications
- 1
- Trial
- 1
- Developer
Indications
3Decrease in night vision
Phase 2, Completed, NCT01703559, clinicaltrials.gov, 11 Oct 2026
Loss disturbance; vision
Phase 2, Completed, NCT01703559, clinicaltrials.gov, 11 Oct 2026
Night vision complaints
Phase 2, Completed, NCT01703559, clinicaltrials.gov, 11 Oct 2026
In the full profile
- Targets and what it contains6
- Owner and partners1
- Trials1
- Evidence for its targets5
- Competitors4
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.